Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1572932A as Adjuvant Therapy in Resectable MAGE-A3 Positive NSCLC
jRCT2080220584Phase 3
- Sponsor
- GSK
- Start
- Aug 2008
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of astuprotimut-R in non-small cell lung cancer (NSCLC), sponsored by GSK.
02
Drugs
astuprotimut-R
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080220584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220584.